Cytokinetics (NASDAQ: CYTK) director receives 151-share equity retainer grant

Rhea-AI Filing Summary

Harrington Robert Arthur reported acquisition or exercise transactions in this Form 4 filing.

Cytokinetics director Harrington Robert Arthur received a grant of 151 shares of common stock on July 15, 2026, under the company’s Equity in lieu of Cash Retainer Program. The shares are fully vested at grant, bringing his direct holdings to 21,932 shares.

Insider Trade Summary

Net Buyer: 151 shares

Net Buy 1 txn

Insider Harrington Robert Arthur

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	151	$82.62	$12K

Holdings After Transaction: Common Stock — 21,932 shares (Direct)

Footnotes (1)

1. F1. Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

Key Figures

Shares granted: 151 shares Grant price per share: $82.62 Total holdings after grant: 21,932 shares +1 more

4 metrics

Shares granted 151 shares Common stock grant on July 15, 2026 under Equity in lieu of Cash Retainer Program

Grant price per share $82.62 Value per share used for the 151-share stock grant

Total holdings after grant 21,932 shares Director’s direct ownership of Cytokinetics common stock following the grant

Transaction date 2026-07-15 Date of the reported stock grant to the director

Key Terms

Equity in lieu of Cash Retainer Program, fully vested, Grant, award, or other acquisition

3 terms

Equity in lieu of Cash Retainer Program financial

"granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program"

fully vested financial

"Shares are fully vested at the time of grant"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/16/2026 - 04:30 PM Accepted by SEC EDGAR 07/16/2026 - 04:29 PM Learn about SEC filing dates

FAQ

What Form 4 transaction did Cytokinetics (CYTK) disclose for Harrington Robert Arthur?

Cytokinetics reported that director Harrington Robert Arthur received a grant of 151 shares of common stock on July 15, 2026. The shares were issued under the company’s Equity in lieu of Cash Retainer Program and are fully vested at the time of grant.

How many Cytokinetics (CYTK) shares does Harrington Robert Arthur hold after this grant?

After this transaction, Harrington Robert Arthur holds 21,932 shares of Cytokinetics common stock directly. This reflects the addition of 151 fully vested shares granted under the company’s Equity in lieu of Cash Retainer Program, with no reported same-day sales or dispositions in this filing.

Was the CYTK stock grant to Harrington Robert Arthur an open-market purchase?

No. The filing shows a Form 4 code A for grant, award, or other acquisition of 151 Cytokinetics shares, not an open-market purchase. The shares came from the Equity in lieu of Cash Retainer Program as compensation, and are fully vested at grant.

What is the price per share used for Harrington Robert Arthur’s CYTK stock grant?

The reported price per share for Harrington Robert Arthur’s Cytokinetics grant is $82.62. This figure represents the value used for the 151-share stock retainer award disclosed on July 15, 2026, rather than a price paid in an open-market transaction.

Are the shares in Harrington Robert Arthur’s CYTK grant vested?

Yes. A footnote states that the 151 Cytokinetics shares granted to Harrington Robert Arthur are fully vested at the time of grant. This means he has immediate ownership and does not need to satisfy future service or performance conditions for these shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harrington Robert Arthur

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A(1)		151	A	$82.62	21,932	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of common stock granted pursuant to the Cytokinetics Equity in lieu of Cash Retainer Program. Shares are fully vested at the time of grant.

	/s/ John Faurescu, attorney-in-fact for Dr. Harrington	07/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)